Their first product, VeraMarker™ BCR, is a blood test for detecting breast cancer and cancer recurrence monitoring, being commercialized as the first metabolite-based test in the world. Matrix-Bio aims to be a leading provider of metabolomics-based testing in the fast-growing molecular diagnostic testing market, exploring the commercial feasibility of additional diagnostics tests using its VeraMarker technology platform for other cancers and predicting preoperative chemotherapy effectiveness for breast cancer treatment.